Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

18-10-2023 | Metformin | Original Article

Clinical impact of metformin exposure during Staphylococcus aureus bacteremia in patients with diabetes mellitus

Authors: Ju Young Lee, Eun Sil Kim, Euijin Chang, Seongman Bae, Jiwon Jung, Min Jae Kim, Yong Pil Chong, Sung-Han Kim, Sang-Ho Choi, Sang-Oh Lee, Yang Soo Kim

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 12/2023

Abstract

Purpose

Increasing evidence has suggested that metformin may play positive roles in a wide range of infectious diseases. This study aimed to investigate the clinical impact of metformin exposure during Staphylococcus aureus bacteremia (SAB) in patients with diabetes.

Methods

A 3-year observational cohort study of 452 patients (aged ≥ 16 years) with SAB was performed at a tertiary care hospital. Metformin exposure was defined as receiving metformin during SAB, regardless of metformin use before the onset of bacteremia.

Results

Of 452 patients, 51 (11.3%) were classified in Group A (diabetes with metformin exposure), 115 (25.4%) in Group B (diabetes without metformin exposure), and 286 (63.3%) in Group C (no diabetes). The 30-day mortality rate in Group A was significantly lower than that in Group B (3.9% [2/51] versus 14.8% [17/115]; p = 0.04) and lower than that in Group C (3.9% [2/51] versus 17.1% [49/286]; p = 0.02). The mortality rates did not differ between Group B and Group C (14.8% [17/115] versus 17.1% [49/286]; p = 0.57). The rates of persistent and recurrent bacteremia were comparable among the three groups. Multivariate analysis indicated that metformin exposure was significantly associated with reduced mortality (adjusted odds ratio, 0.20; 95% confidence interval, 0.04–0.88; p = 0.03).

Conclusions

Metformin exposure during SAB appears to be an independent predictor of survival in patients with diabetes.

Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VG (2015) Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 28:603–661. https://doi.org/10.1128/CMR.00134-14CrossRefPubMedPubMedCentral

Smit J, Sogaard M, Schonheyder HC, Nielsen H, Froslev T, Thomsen RW (2016) Diabetes and risk of community-acquired Staphylococcus aureus bacteremia: a population-based case-control study. Eur J Endocrinol 174:631–639. https://doi.org/10.1530/EJE-16-0023CrossRefPubMed

Hansen MU, Gotland N, Mejer N, Petersen A, Larsen AR, Benfield T, Danish Staphylococcal Bacteremia Study Group (2017) Diabetes increases the risk of disease and death due to Staphylococcus aureus bacteremia. A matched case-control and cohort study. Infect Dis (Lond) 49:689–697. https://doi.org/10.1080/23744235.2017.1331463CrossRefPubMed

Kaasch AJ, Barlow G, Edgeworth JD, Fowler VG, Hellmich M, Hopkins S, Kern WV et al (2014) Staphylococcus aureus bloodstream infection: A pooled analysis of five prospective, observational studies. J Infect 68:242–251. https://doi.org/10.1016/j.jinf.2013.10.015CrossRefPubMed

Malik F, Mehdi SF, Ali H, Patel P, Basharat A, Kumar A, Ashok F et al (2018) Is metformin poised for a second career as an antimicrobial? Diabetes Metab Res Rev 34:e2975. https://doi.org/10.1002/dmrr.2975CrossRefPubMed

Liang H, Ding X, Li L, Wang T, Kan Q, Wang L, Sun T (2019) Association of preadmission metformin use and mortality in patients with sepsis and diabetes mellitus: a systematic review and meta-analysis of cohort studies. Crit Care 23:50. https://doi.org/10.1186/s13054-019-2346-4CrossRefPubMedPubMedCentral

Garnett JP, Baker EH, Naik S, Lindsay JA, Knight GM, Gill S, Tregoning JS et al (2013) Metformin reduces airway glucose permeability and hyperglycaemia-induced Staphylococcus aureus load independently of effects on blood glucose. Thorax 68:835–845. https://doi.org/10.1136/thoraxjnl-2012-203178CrossRefPubMed

Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W et al (2002) Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 137:791–797. https://doi.org/10.7326/0003-4819-137-10-200211190-00007CrossRefPubMed

Oliveira DC, de Lencastre H (2002) Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 46:2155–2161. https://doi.org/10.1128/AAC.46.7.2155-2161.2002CrossRefPubMedPubMedCentral

10.

Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG (2000) Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol 38:1008–1015. https://doi.org/10.1128/JCM.38.3.1008-1015.2000CrossRefPubMedPubMedCentral

11.

Jarraud S, Mougel C, Thioulouse J, Lina G, Meugnier H, Forey F, Nesme X et al (2002) Relationships between Staphylococcus aureus genetic background, virulence factors, agr groups (alleles), and human disease. Infect Immun 70:631–641. https://doi.org/10.1128/IAI.70.2.631-641.2002CrossRefPubMedPubMedCentral

12.

Rena G, Hardie DG, Pearson ER (2017) The mechanisms of action of metformin. Diabetologia 60:1577–1585. https://doi.org/10.1007/s00125-017-4342-zCrossRefPubMedPubMedCentral

13.

Owen MR, Doran E, Halestrap AP (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348:607–614. https://doi.org/10.1042/bj3480607CrossRefPubMedPubMedCentral

14.

Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, Prigaro BJ et al (2014) Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510:542–546. https://doi.org/10.1038/nature13270CrossRefPubMedPubMedCentral

15.

Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Manneras-Holm L, Stahlman M et al (2017) Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med 23:850–858. https://doi.org/10.1038/nm.4345CrossRefPubMed

16.

Schuiveling M, Vazirpanah N, Radstake TRDJ, Zimmermann M, Broen JCA (2018) Metformin, a new era for an old drug in the treatment of immune mediated disease? Curr Drug Targets 19:945–959. https://doi.org/10.2174/1389450118666170613081730CrossRefPubMed

17.

Lv Z, Guo Y (2020) Metformin and its benefits for various diseases. Front Endocrinol (Lausanne) 11:191. https://doi.org/10.3389/fendo.2020.00191CrossRefPubMed

18.

Patkee WRA, Carr G, Baker EH, Baines DL, Garnett JP (2016) Metformin prevents the effects of Pseudomonas aeruginosa on airway epithelial tight junctions and restricts hyperglycaemia-induced bacterial growth. J Cell Mol Med 20:758–764. https://doi.org/10.1111/jcmm.12784CrossRefPubMedPubMedCentral

19.

Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK (2014) Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 312:2668–2675. https://doi.org/10.1001/jama.2014.15298CrossRefPubMedPubMedCentral

20.

Magliano DJ, Harding JL, Cohen K, Huxley RR, Davis WA, Shaw JE (2015) Excess risk of dying from infectious causes in those with type 1 and type 2 diabetes. Diabetes Care 38:1274–1280. https://doi.org/10.2337/dc14-2820CrossRefPubMed

21.

Zoppini G, Fedeli U, Schievano E, Dauriz M, Targher G, Bonora E, Corti MC (2018) Mortality from infectious diseases in diabetes. Nutr Metab Cardiovasc Dis 28:444–450. https://doi.org/10.1016/j.numecd.2017.12.007CrossRefPubMed

Title: Clinical impact of metformin exposure during Staphylococcus aureus bacteremia in patients with diabetes mellitus
Authors: Ju Young Lee
Eun Sil Kim
Euijin Chang
Seongman Bae
Jiwon Jung
Min Jae Kim
Yong Pil Chong
Sung-Han Kim
Sang-Ho Choi
Sang-Oh Lee
Yang Soo Kim
Publication date: 18-10-2023
Publisher: Springer Berlin Heidelberg
Keywords: Metformin
Diabetes
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 12/2023
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-023-04679-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2023

Prevalence of Ureaplasma species among patients at a tertiary hospital in China: a 10-year retrospective study from 2013 to 2022

Core genome multilocus sequence typing of Clostridioides difficile to investigate transmission in the hospital setting

Co-regulation of biofilm formation and antimicrobial resistance in Acinetobacter baumannii: from mechanisms to therapeutic strategies

Effectiveness of a multimodal intervention to improve blood culture collection in an adult emergency department

Multicenter interlaboratory study of routine systems for the susceptibility testing of temocillin using a challenge panel of multidrug-resistant strains

Production of OXA-48 carbapenemase acts as an independent risk factor for poor outcome in Klebsiella pneumoniae infection

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials